share_log

諾輝健康:內幕消息 延遲刊發2023年年度業績;延遲召開董事會會議;及暫停買賣

NH HEALTH: INSIDE INFORMATION DELAY IN PUBLICATION OF THE 2023 ANNUAL RESULTS;POSTPONEMENT OF BOARD MEETING;AND SUSPENSION OF TRADING

香港交易所 ·  Mar 28 10:52
Summary by Moomoo AI
諾輝健康(NH HEALTH)於2024年3月28日宣布,由於核數師德勤關黃陳方會計師行提出對ColoClear及Pupu Tube或UU Tube銷售交易的有效性等若干關注事項,需要進行獨立調查,因此無法按時公佈截至2023年12月31日止的年度業績。該公司已委聘第三方專家進行調查,並正與核數師及審核委員會合作解決問題。由於未能如期公佈財務業績,原定於2024年3月28日的董事會會議將延遲召開。此外,根據上市規則,公司股份已於2024年3月28日起暫停買賣,直至年度業績公佈為止。
諾輝健康(NH HEALTH)於2024年3月28日宣布,由於核數師德勤關黃陳方會計師行提出對ColoClear及Pupu Tube或UU Tube銷售交易的有效性等若干關注事項,需要進行獨立調查,因此無法按時公佈截至2023年12月31日止的年度業績。該公司已委聘第三方專家進行調查,並正與核數師及審核委員會合作解決問題。由於未能如期公佈財務業績,原定於2024年3月28日的董事會會議將延遲召開。此外,根據上市規則,公司股份已於2024年3月28日起暫停買賣,直至年度業績公佈為止。
NH HEALTH (NH HEALTH) announced on 28 March 2024 that due to the need for an independent investigation, due to certain concerns raised by Auditor, Dokian Guan Wong Chan Fang, on the effectiveness of the ColoClear and Pupu Tube or UU Tube sales transactions, the annual results for the year ended 31 December 2023 could not be published on time. The company has appointed third-party experts to conduct the investigation and is working with auditors and audit committees to resolve the issue. Due to the failure to publish financial results on time, the Board meeting originally scheduled for 28 March 2024 will be delayed. In addition, under the rules of the listing, the company's shares have been suspended from 28 March 2024 pending the announcement of the annual results.
NH HEALTH (NH HEALTH) announced on 28 March 2024 that due to the need for an independent investigation, due to certain concerns raised by Auditor, Dokian Guan Wong Chan Fang, on the effectiveness of the ColoClear and Pupu Tube or UU Tube sales transactions, the annual results for the year ended 31 December 2023 could not be published on time. The company has appointed third-party experts to conduct the investigation and is working with auditors and audit committees to resolve the issue. Due to the failure to publish financial results on time, the Board meeting originally scheduled for 28 March 2024 will be delayed. In addition, under the rules of the listing, the company's shares have been suspended from 28 March 2024 pending the announcement of the annual results.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more